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ABSTRACT  
For therapeutic studies, predictive validity of animal models - arguably the most important feature 
of animal models in terms of human relevance - can be calculated retrospectively by obtaining data 
on treatment efficacy from human and animal trials. Using rosiglitazone as a case study, we aim to 
determine the predictive validity of animal models of diabetes, by analyzing which models perform 
most similarly to humans during rosiglitazone treatment in terms of changes in standard diabetes 
diagnosis parameters (glycosylated hemoglobin (HbA1c) and fasting glucose levels). A further 
objective of this article is to explore the impact of four covariates on the predictive capacity: i) 
diabetes induction method, ii) drug administration route, iii) sex of animals, and iv) diet during the 
experiments. 
Despite the variable consistency of animal species-based models with the human reference for 
glucose and HbA1c treatment effects, our results show that glucose and HbA1c treatment effects in 
rats agreed better with the expected values based on human data than in other species. Induction 
method was also found to be a substantial factor affecting animal model performance. 
The study concluded that regular reassessment of animal models can help to identify human 
relevance of each model and adapt research design for actual research goals 
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INTRODUCTION  
Although animal research is considered to be a central element of contemporary biomedical science 
and arguably has contributed greatly to the understanding of disease mechanisms and 
development of treatments, the predictive validity of different animal models is generally assumed 
and rarely measured. Having information on this feature of animals is crucial especially for 
therapeutic studies. The predictive validity of animal models which means ‘to what extent research 
data from animals can predict human response to particular drugs’ can be calculated 
retrospectively, after obtaining data on treatment efficacy from humans and animals. 
Even though only human-animal comparative studies can produce evidence on human relevance of 
animal models and justify their use from a scientific point of view, relatively few studies have 
addressed their methodology. Several animal studies speculate on the translatability of results from 
animal studies by assuming on the validity of animal models. However, unique characteristics of 
animals models deserve special consideration on whether results can be translated to humans or 
not 
1
. As Garth Whiteside has noted, comparison of large datasets from preclinical efficacy studies 
and human trials is a complex matter, and the predictive capacity of these models cannot be 
described as “worked”, “didn’t work”, or “failed”; deeper analysis is needed 
2
.  
To evaluate the predictive validity of animal models, one may opt for 1) assessing the predictive 
validity of a single or very few models by comparing treatment effects of series of interventions 
(e.g. administration of anti-diabetic drugs) in that/those animal model(s) and humans, or 2) 
assessing the predictive validity of several animal models by comparing the treatment effect of a 
particular intervention in those animals and humans. In either case, this comparison should be 
based on quantitative data that allow correlations between humans and different animal species to 
be calculated. This requires access to data where the same quantitative information (outcomes) is 
available for treatment effects both in animal and human subjects. Although research outcomes of 
an identical nature are regularly reported in human and animal studies, any study selection effort 
entails the setting of minimum criteria for study design quality. Furthermore, data availability is also 
an issue.  
The quality of the data has a huge impact on the conclusions what can be drawn but raw data are 
rarely presented. The ideal human data for the calculation would be complete data from clinical 
trials. Due to the recent tight regulations on clinical trials (e.g. requirement of authorization 
3
 and 
prior registration 
4
), transparency on the conduct and results of clinical trials has been improved. 
However, there are still problems with study design and publication from these trials. Regarding 
design, a widely discussed issue among others is the obscure management of missing data 
5
. 
Additionally, we know that not all studies get published in their entirety after the clinical trials 
6
; 
what is more, what does get published may be different from in-house interpretation and more 
likely to make a drug look favorable 
7
.  
Also for animal data, it is increasingly evident that shortcomings in research design and publication 
bias resulting from selective publishing of desirable results are the cause of overestimated 
treatment effects 
8, 9
. The retrospective evaluation of the predictive validity of animal models is 
further complicated by statistical weaknesses. Animal studies regularly report data from small 
samples of animals, and usually such studies are not repeated by independent third party 
laboratories. 
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An additional challenge is that of comparing different species 
10
. The efficient drug dose widely 
varies across species, mostly due to the pharmacokinetics of a particular drug being different from 
species to species 
11
. It is commonly observed that small animals need to be administered larger 
doses (per kilogram body weight) as compared to big animals or humans to achieve similar 
pharmacological effects. For instance, about five-fold higher doses of prednisolone and caffeine 
have been reported for rats as compared to humans 
12
. Providing cross-species comparisons of 
activity and toxicity of various drugs, two important methods are used for dosage conversions. One 
is based on per body surface area (BSA) calculation (mg/m
2
) which is the method required by the 
FDA; the alternative method considers the daily expenditure of energy expressed per metabolically 
active mass (MAM) 
12
. 
In the present paper, we propose a method for assessing the predictive validity of several animal 
models. Using rosiglitazone, a widely used pharmaceutical to treat type 2 diabetes mellitus, we 
aimed to provide data on the predictive validity of different animal models of diabetes. Type 2 
diabetes was chosen since animal models are widely used in research into this disease 
13
 but their 
predictive validity has never been statistically studied. Rosiglitazone is an ideal case study to test 
the predictive validity of diabetes animal models: it is widely used in human patients and a 
preliminary PubMed search showed it to be the most commonly used pharmaceutical in animal 
studies into type 2 diabetes.  
The main objective of this article is to determine the predictive validity of animal models of 
diabetes, by analyzing which models perform most similarly to humans during rosiglitazone 
treatment in terms of changes in standard diabetes diagnosis parameters (glycosylated hemoglobin 
(HbA1c) and fasting glucose (FG) levels).  A further objective of this article is to explore the impact 
of four covariates on the predictive capacity of animal models. These covariates are methodological 
issues which often differ across studies, namely i) diabetes induction method, ii) drug 
administration route, iii) sex of animals, and iv) diet during the experiments. 
MATERIAL AND METHODS 
Literature review 
Both human and animal studies were searched between September and December 2012. Studies 
reporting rosiglitazone monotherapies with information on glucose and/or HbA1c, published in 
English, were included. All references were downloaded and managed in Endnote. Two authors 
(OEV, NZs) assessed studies and extracted data into an excel table (Microsoft Office Excel 2007). 
Data on study design elements including time, route and dose of the drug administration, the 
species and strain of the animal, age and sex/gender of subjects, diets, diabetes induction method, 
outcomes (i.e. FG and HbA1c levels - number of observations, mean, variability measure) in each 
study group were extracted. In those papers where data was only reported graphically, a digital 
online ruler 
14
 was used to gain numerical values. 
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Animal studies were identified from Pubmed and Web of Science using the following algorithms. 
Pubmed search: ("animal experimentation"[MeSH Terms] OR "models, animal"[MeSH Terms]) AND 
"rosiglitazone"[Supplementary Concept] AND "blood glucose"[MeSH Terms]. Web of Science: 
Topic=(rosiglitazone) AND Topic=(blood glucose) AND Topic=(animal) AND Topic=(search filter 
suggested by Carlijn R Hooijmans
15
). The selection method with exclusion criteria is presented in 
Figure 1A. A total of 71 studies were included. 
Figure. 1. Procedure on selection of studies. (A): Procedure chart on how animal studies were 
selected. (B): Procedure chart on how human studies were selected.   
Human studies were identified from three sources. A PubMed search that used the algorithm: 
“Blood Glucose”[Mesh] AND “Hemoglobin A, Glycosylated”[Mesh] AND “Diabetes Mellitus, Type 
2/drug therapy”[Mesh] AND “rosiglitazone”[Supplementary Concept] AND 
“Thiazolidinediones/therapeutic use”[Mesh] AND “Randomized Controlled Trial”[ptyp] AND 
English[lang]. In addition, one study 
16
 from a published metaanalysis on the efficacy of 
thiazolidinediones (the class of drugs that include rosiglitiazone) in the Asian population 
17
 was 
included. Finally, all monotherapy studies were identified and included in the analysis from the 
website of the pharmaceutical company GlaxoSmithKline (GSK) who made all studies on 
rosiglitazone available through the company’s website 
18
. Details along with exclusion criteria are 
shown in Figure 1B.  
Parameters and factors analyzed 
To evaluate the predictive capacity of different animal models, human and animal glycosylated 
hemoglobin (HbA1c) and fasting glucose (FG) levels were selected as outcome measures. HbA1c is 
the primary laboratory test for diabetes in human studies and reflects average blood glucose for the 
preceding 60 to 90 days, whereas FG level is a very common parameter to monitor diabetes. 
To evaluate the effect of certain factors which often differ across studies and may cause 
methodological issues, the following were considered: i) diabetes induction method; ii) drug 
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administration route; iii) sex of animals; and iv) diet during experiments. Rationale of selecting 
these covariates is given below.  
i) A number of diabetic animal models have been developed over the years, based mostly on 
rodents; these models can be classified into two broad categories: 1) genetically induced 
spontaneous diabetes models and 2) experimentally induced (non-spontaneous) diabetes models 
19
. The second consists of several subtypes: streptozotocin (STZ)/alloxan models, partial 
pancreatectomy models, high-fat (HF)/high-sucrose diet-fed models, HF diet-fed STZ models, and 
intrauterine growth retardation (IUGR) models 
19
.  
ii) Several drug administration methods have been used to introduce the chemical substance. Oral 
administration, subcutaneous administration, and intra-peritoneal injection of substances are 
common procedures in scientific experiments 
20
.  
iii) Since diet has a significant impact on diabetes induction and progress, diet is a crucial part of the 
experimentation, whether spontaneous or experimentally induced models are used 
21
.   
iv) The sex of animals has a well-documented impact on diabetes mellitus progress, which may 
imply gender-specific clinical treatment of diabetes 
22
.  
Statistical modeling and analysis 
Information from all included studies was extracted and entered into a single database with as 
many observations for each study as the number of fasting glucose and/or HbA1c outcome 
measurements reported at distinct follow-up times in that study. Outcome level means and their 
standard errors were logarithmically transformed (natural base) using appropriate formulas to 
derive the expected value and standard error of the transformed variable working from the mean 
and standard error of the source variable. Treatment effect estimates at each observation time 
were calculated as the between-groups (rosiglitazone versus placebo) difference in transformed 
outcome levels. Treatment effect standard errors were calculated as the square root of the sum of 
group-specific squared standard errors. For the analysis of species effect, only rats and mice were 
included, whereas the remaining analyses were done on the complete dataset, including the two 
single studies on hamster and gerbil.  For this reason animal strains in Figure 2A and 2B, are referred 
to as “Rat” and “Mouse”. 
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Linear regression models were fitted on human observations for both outcomes. The dependent 
variable was the treatment effect; explanatory variables included dose, time into exposure (natural 
logarithm of week) complete with a quadratic derivative, and interaction terms between dose and 
time. Observations were weighted proportionally to their precision (reciprocal of squared standard 
error of treatment effect). The distribution of dose values was bimodal; a low vs high dose 
categorization cutoff of 6.5 mg was observed to coincide with a fairly wide gap between the two 
modes, close to the sample 50
th
 percentile. To verify that this categorization did not cause 
substantial loss to model fit and/or changes to results and conclusions, the analysis was also 
completed using dose as a continuous variable, transforming rat doses (mg intake) to a human-
comparable scale dividing by 2.25, and non-rat murine doses by dividing by 11.25, in accordance 
with FDA guidelines regarding interspecies dose conversion 
3
. Model fit was evaluated using 
normality tests of residuals and Ramsey’s regression specification-error tests, neither of which 
indicated any insufficiency of fit (all P ≥ 0.195).  
Coefficients derived from the human models were used to calculate expected values of non-human 
treatment effects. For each included study, and for each level of strain, diabetes induction method, 
special diet (yes or no), sex, and drug administration route within the study if applicable, differences 
between observed and expected treatment effects were squared, summed, divided by the number 
of measurement occasions, and taken the square root of. Values so derived were referred to as 
deviation scores. 
The effects of factors raising methodological issues, such as species, induction method, diet, sex, 
and administration route were evaluated by comparing groups in terms of deviation scores. Basic 
unadjusted comparisons were made using simple linear regression. Adjusted effect estimates were 
obtained using multiple linear regression. Deviation scores were log-transformed to improve 
normality. Robust standard errors based on the clustering of observations within studies were used 
to make the estimation consistent with the presence of non-independence between observations 
coming from the same study. Explanatory variables with negligible effect estimates on both 
outcomes and no appreciable role as adjustment or interaction factors were eliminated to ensure 
model parsimony. 
All statistical calculations and analyses were done using the software package Stata version 11. The 
detailed protocol of data collection and analysis is available as Supporting Information 1. 
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RESULTS 
General description of dataset 
As a result of rosiglitazone treatment, hyperglycemia ameliorated in both diabetic animals and 
T2DM patients. The dose used to efficiently reduce blood glucose and HbA1c levels in animals 
varied considerably across studies (6-20 mg/kg).  Generally speaking, higher doses are used in 
animals than humans. In T2DM patients, rosiglitazone reduced fasting blood glucose and HbA1c 
levels at a daily dose of 4-8 mg. Animal studies differed from studies in human patients in terms of 
the age of study subjects: the initial age of human patients corresponded to late adulthood whereas 
that of animals represented adolescence and early adulthood. In animal studies the impact of 
treatment was detected by a comparison of glucose and HbA1c levels between treatment and 
placebo groups, whereas 30 out of 62 human studies presented data as compared to baseline 
measurements (see Figure 1), that could not be used for our analysis. Table 1 shows main 
characteristics of study subjects and glucose and HbA1c parameters from human and animal 
studies. 
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Table 1. Characteristics of subjects in the studies.  
 Human Rat Mouse Gerbil Hamster 
List of strains (number 
of studies, number of 
animals) 
22, 3076 Brown 
Norway (1, 
18) 
(apo)E2 knock-in mice (1, 
20) 
gerbil 
(1, 32) 
Syrian 
Golden (1, 
30) 
Dahl 
SS/JrHsd (1, 
20) 
A-ZIP (1, 12) 
Goto 
Kakizaki (1, 
13) 
BALB/c (1, 40) 
LETO (1, 10) C57BL6J (3, 70) 
OLETF (1, 
10) 
DBA/2J (1, 63) 
Ob-ZSF1 (1, 
30) 
FVB/N (1, 12) 
Sprague 
Dawley (12, 
293) 
KKAgamma (1, 12) 
Wistar (9, 
189) 
Ldlr-/-
Apob100/100Lepob/ob (1, 
23) 
ZDF (14, 
251) 
MKR (1, 12) 
Zucker lean 
(2, 32) 
Swiss albino (2, 30) 
apoE deficient (2, 96) 
db/db (14, 214) 
ob/ob (4, 52) 
initial age, weeks - 
weighted arithmetic 
mean (SD) 
58.50 
(8.93) 
years 
8.59 (4.51) 7.05 (2.53) 16.00 
(0.00) 
9.00 (0.00) 
Experimental time, 
weeks 
27.09 
(15.10) 
5.47 (5.44) 8.53 (7.05) 2.00 
(0.00) 
5.00 (0.00) 
Average  dose used, 
mg/kg/day 
4.87 
(2.00) 
6.49 (6.95) 11.59 (15.48) 20.00 
(0.00) 
7.15 (0.00) 
Glucose level after 
treatment, mmol/l 
8.44 
(2.21) 
10.58 (2.57) 13.28 (8.72) 6.34 
(3.70) 
3.50 (2.32) 
HbA1c  after 
treatment, % 
7.69 
(1.13) 
4.71 (0.73) 7.19 (2.93) no 
data 
 
no data 
 
Information provided in the table is based on all study subjects either treated with rosiglitazone or 
receiving no treatment, except for the rows “Glucose level after treatment” and “HbA1c after 
treatment” which include only treated groups. Means and standard deviations were pooled across 
studies by weighted averaging based on sample sizes, means and standard deviations reported for 
each study. 
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Comparing the consistency of animal models with the human reference for glucose and HbA1c 
treatment effects 
All analyses shown below refer to models using dose as a categorical factor as no appreciable 
differences from results obtained with the continuous formulation were observed. 
Rodent models roughly agreed with human data, especially for rats, but showed considerably 
varied accuracy in reflecting the efficacy of rosiglitazone in humans. For clarity, data on human-
scaled values are provided in Table 2. The table shows how glucose and HbA1c levels differed in the 
rosiglitazone versus the placebo arms in humans at various time points into follow up. For example, 
in low dose treatment at three weeks, the average glucose level in the rosiglitazone arms was 
85.9% of that in the placebo arms, or, in other words, a reduction of about 14% can be estimated as 
the treatment effect. For simplicity, data at median and terminal follow up time points were used to 
illustrate the tendencies. 
Table 2. Ratios of glucose and HbA1c levels between the Rosiglitazone and placebo arms in human 
studies at different times into follow up.  
 Fasting glucose level ratios, 
rosiglitazone vs placebo 
 
HbA1c level ratios, rosiglitazone vs 
placebo 
 
low dose group, 
median follow-
up  
 
 
3 weeks 0.859 [0.478 to 
1.545] 
 
8 weeks 
 
0.940 [0.908 to 
0.974] 
 
low dose group, 
end of follow-up  
52 weeks 
 
0.817 [0.691 to 
0.965] 
 
52 weeks 
 
0.894 [0.811 to 
0.985] 
 
high dose group, 
median follow-
up  
3 weeks 
 
1.056 [0.976 to 
1.143] 
 
8 weeks 
 
1.027 [0.998 to 
1.057] 
 
low dose group, 
end of follow-up  
52 weeks 
 
0.870 [0.824 to 
0.918] 
 
52 weeks 
 
0.992 [0.953 to 
1.034] 
 
Square brackets include 95% confidence intervals 
Analysis of the 69 publications reporting studies with rats and mice (the single hamster and gerbil 
study excluded from this analysis) showed that the consistency of animal species-based models 
with the human reference for glucose and HbA1c treatment effects is highly variable. Glucose and 
HbA1c treatment effects in rats agreed better with the expected values based on human data than 
in mice, indicating that rat-based models may have greater consistency than those based on other 
species. Figure 2A shows that rats had significantly lower scores of deviation from the human 
reference than mice for glucose treatment effects during rosiglitazone treatment (means: 0.275 vs 
0.594, respectively; P = 0.0023, unadjusted analysis). In case of HbA1c treatment effects, rats had 
the lowest deviation scores again (0.385 on average, vs 0.639 in mice), and the unadjusted 
difference was borderline significant (Figure 2B, P = 0.0446). 
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Strains 
The question regarding which strain is the most appropriate to model the clinical efficacy of 
rosiglitazone could not be conclusively answered. In the analysed studies ten rat strains, eleven 
mouse strains, and two other species were used. Although SD rats and C57BL/6 mice seemed to be 
the most consistent animal models for the clinical efficacy of rosiglitazone, no statistical difference 
in deviation scores was observed between groups. The strain presenting the least consistent results 
for the clinical efficacy of rosiglitazone (in terms of both glucose and HbA1c treatment effects, with 
mean deviation scores 0.801 and 0.698, respectively) was the commonly used db/db mouse. Data 
on rat and mouse models are presented in Figure 2C. 
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Figure. 2. Comparing the animal models with the human reference for glucose and HbA1c 
treatment effects. (A): Deviation scores for glucose treatment effects under rosiglitazone 
monotherapy in mice and rats. Horizontal lines of pluses indicate sample means; n denotes number 
of observations. (B): Deviation scores for HbA1c treatment effects under rosiglitazone 
monotherapy in mice and rats. Horizontal lines of pluses indicate sample means; n denotes number 
of observations. (C): Deviation scores for glucose treatment effects under rosiglitazone 
monotherapy in rat and mouse strains. Horizontal lines of pluses indicate sample means. Strains 
rarely used in studies are pooled as “other mouse” and “other rat”; n denotes number of 
observations 
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Impact of animal study covariates - induction method, drug administration route, sex of animals and 
applied diet  
From the point of view of similarity to the human response to rosiglitazone, STZ induction was 
observed to be the most appropriate induction method, as presented in Figure 3A. STZ-induced 
diabetic animal models had the highest average consistency (mean deviation score: 0.237) with the 
human reference as evaluated in terms of the treatment effects of rosiglitazone on glucose levels. 
Performing a similar analysis for HbA1c was not practicable due to the low number of relevant 
studies.  
Comparing the three administration methods, oral gavage was associated with the lowest deviance 
scores (mean: 0.369 for glucose, 0.449 for HbA1c). Of note, the number of observations for 
peritoneal administration was relatively small, and the unadjusted difference was only borderline 
significant for glucose (Figure 3B) and non-significant for HbA1c (Figure 3C).To test the hypothesis 
that humanized (high-sucrose, high-fat) or other diets could have an impact on diabetes onset and 
progress, and thereby on the consistency between animal and human models, deviation scores 
were compared across groups defined by high-sucrose, high-fat, high-sucrose-high-fat, and low-fat 
diets. No link was found between diet and the performance of animal models. Similarly, the sex of 
the animals was not observed to affect the deviation between animal and human models. Raw data 
associated with factors representing covariates are shown in Table 3.  
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Table 3. Description of factors that may cause methodological issues (covariates) in animal studies.  
 Rat Mouse Gerbil Hamster 
Induction method 
(number of studies, 
number of animals) 
SP (27, 350) 
 
GM (6, 58) SP (1, 
16) 
SP (1, 15) 
SP+STZ (1, 8) GM+STZ (2, 24) 
SP/diet (1, 10) SP (21, 208) 
alloxan (1, 5) dexamethasone 
(1, 7) 
dexamethasone 
(1, 6) 
streptozotocin (5, 
101) 
diet (2, 14) 
low protein IU 
diet (1, 7) 
streptozotocin 
(13, 135) 
surgery (1, 20) 
Administration route 
(number of studies, 
number of animals) 
per os (14, 139) 
 (1, 10) 
per os (12, 129) oral 
gavage 
(1, 16) 
oral 
gavage 
(1, 15) oral gavage (24, 
394) 
oral gavage (15, 
250) 
intraperitoneal 
injection (1, 12) 
intraperitoneal 
injection (2, 13) 
unknown (1, 10) unknown (1, 6) 
Diets (number of studies, 
number of animals) 
high-NaCl (1, 10) 
 
high-fat (6, 103) high-
energy 
(1, 16) 
high-fat 
(1, 15) 
high-fat (7, 77) low-fat (1, 5) 
high-fat-high-
sucrose (1, 8) 
normal diet (21, 
275) 
normal diet (24, 
265) 
unknown diet (2, 
15) 
unknown diet (8, 
195) 
Sex in animals in 
absolute numbers 
(male/female/both or 
unknown) 
401/36/118 318/18/62 16/0/0 15/0/0 
GM, genetically induced models; SP, spontaneous diabetes models; STZ, streptozotocin models; 
IU, intrauterine 
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Figure. 3. Impact of animal study covariates. (A): Deviation scores for glucose treatment effects 
under rosiglitazone monotherapy in groups by diabetes induction method. "STZ only" denotes the 
use of streptozotocin (STZ) only; "SP only", the absence of exogenous (non-spontaneous) induction 
methods; "other" denotes models that were not used frequently enough for individual analysis 
(alloxan models, partial pancreatectomy  models, high-fat/high-sucrose diet-fed models, high-fat 
diet-fed STZ models, and intrauterine growth retardation models). Horizontal lines of pluses 
indicate sample means; n denotes number of observations. (B): Deviation scores for glucose 
treatment effects under rosiglitazone monotherapy in groups by drug administration route. 
Horizontal lines of pluses indicate sample means; n denotes number of observations. (C): Deviation 
scores for HbA1c treatment effects under rosiglitazone monotherapy in groups by drug 
administration route. Horizontal lines of pluses indicate sample means; n denotes number of 
observations.   
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In multiple regression analysis, species, induction method, and drug administration route were 
found to be substantial factors of animal model performance (Table 4). Adjusted for induction 
method and administration route, rat models performed better: the difference in deviation scores 
between rats and other species was strongly significant for the fasting glucose outcome, although 
not quite for HbA1c. STZ as an induction method was found to better approximate the relationship 
between rosiglitazone exposure and treatment effect, observed in humans, than other methods, 
especially when treatment effect was assessed through HbA1c levels. The data also suggests that 
intraperitoneal administration may result in poorer consistency between human and animal models 
than per os administration. 
Table 4. Additive effects of animal study factors on deviation scores of animal models  
Factor Contrast Effect 95%CI p 
Outcome: fasting glucose 
Species rat vs mouse -0.790 -1.255 -0.325 0.001 
Intervention SP only vs STZ only 0.505 -0.086 1.097 0.093 
Intervention other vs STZ only 0.151 -0.722 1.023 0.731 
Administration route oral gavage vs per os -0.188 -0.666 0.290 0.434 
Administration route intraperitoneal vs per os 0.650 0.130 1.169 0.015 
Outcome: HbA1c 
Species rat vs mouse -1.577 -3.257 0.103 0.063 
Intervention SP only vs STZ only 3.179 1.020 5.339 0.008 
Intervention other vs STZ only 4.937 2.494 7.379 0.001 
Administration route oral gavage vs per os -0.867 -2.131 0.397 0.159 
Additive effects of animal study factors on deviation scores of animal models with respect to the 
human reference for the relationship between rosiglitazone exposure and treatment effect on 
follow-up levels of fasting glucose and HbA1c. CI, confidence interval 
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DISCUSSION 
Clear understanding on the predictive validity of animal models is in those fields of applied drug 
testing where several animal models are used. In this study we presented a method to statistically 
evaluate the predictive validity of animal model studies. Using rosiglitazone in diabetes as a case 
study and comparing treatment effects between human and animal studies, we showed that 
studies in rats are better predictors of results in humans than other animal model studies. 
Agreement between human and animal studies was further affected by disease induction method 
and drug administration route. This was the first time that the concept of predictive capacity of 
animal models was systematically approached in type 2 diabetes pharmaceutical studies.  
Our case study of rosiglitazone had two research questions: to compare treatment effect of 
rosiglitazone in human and animal models in order to identify which is more relevant to humans, 
and to understand the impact of experimental diet, induction method, sex, and administration 
route of rosiglitazone on the treatment effect of rosiglitazone. 
According to the research question on the human relevance of animal models, our findings showed 
that although the consistency of animal species-based models with the human reference for 
glucose and HbA1c treatment effects are highly variable, glucose and HbA1c treatment effects in 
rats agreed better with the expected values based on human data than in other species; rats had 
significantly lower scores of deviation from the human reference than mice for glucose and HbA1c 
treatment effects. The question regarding which strain is the most appropriate to model the clinical 
efficacy of rosiglitazone could only be tentatively answered. There was no statistical difference in 
deviation scores observed between rat groups; among mouse strains, C57BL/6 showed the most 
consistent, while db/db showed the least consistent results.  
Since models differ in physiological and genetic relevance, there is no  single diabetic animal model 
which would fit for all scientific purposes; ideally, more than one species or strain are used in each 
study 
13
. Three different approaches are used to evaluate the reliability of animal models: the first is 
phenomenological/pathophysiological similarity of the model to the syndrome it is imitating (face 
validity), the second compares  the etiology of diseases in animal models and humans (construct 
validity), and the third approach refers to the ability of the model to respond to appropriate 
medications (predictive validity) 
23
. The vast majority of reviews on T2DM animal models gives 
information on the models’ face and construct validity, categorized by species. The characteristics 
of often used species such as murine models 
24
, or monkeys 
25
 or canines 
26
, or pigs 
27
 are widely 
discussed. As it was noted, very few studies on T2DM addressed the translatability of animal 
research results to humans and how to select animal models with “higher human relevance”. A 
recent study has pointed out that genetic similarities between humans and certain species can be 
useful for appropriate model selection 
28
 and another study categorized mouse models by outcome 
measures that are used in the clinical practice of diabetic nephropathy 
29
.  
A generally good correlation between human and animal experimental outcomes is often assumed 
in pharmacological studies, not considering the impact of the species effect. For example, the use 
of the leptin-deficient mouse (ob/ob) in type 2 diabetes research is widely recommended in any 
pharmaceutical research 
30
 but our case study does not prove “high predictive validity of this model” 
for rosiglitazone efficacy in humans. This example points out that if we want to understand how 
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reliable our animal models are in a particular situation, results must be (re)assessed in the light of 
human data. 
Concerning our second research question, in multiple regression analysis, induction method, and 
drug administration route were studied, and the induction method was found to be a substantial 
factor affecting animal model performance. STZ as an induction method was associated with better 
approximation of the human relationship between rosiglitazone exposure and treatment effect 
than other methods, especially when treatment effect was ascertained through HbA1c levels. 
Although this result gives significant input for experimental design, it has to be underlined that 
these specific comparisons were complicated because HbA1c level, which is the primary outcome of 
human studies, was less frequently reported in animal studies  
30
.  
There are several established methods for determining glycated hemoglobins
31
 and many of them 
are used in rodents
32
. The relation between HbA1C and plasma glucose levels in diabetes animal 
models has also been well described
33
. However, in an ideal case, free plasma concentration of 
rosiglitazone could be compared between human and animal subjects, and identify how much of 
the drug is in the blood.  
One of the strengths of this study is that to ensure sufficient coverage of relevant literature, it goes 
beyond traditional information sources; data from unpublished human studies have also been 
involved in the analysis. A very complex and long lawsuit filed against GSK started in 2007. One of 
the consequences of the legal action against GSK was that all studies performed by the company 
were made available through the company’s website 
18
 and thus became available for our analysis. 
On the other hand, there are specific limitations to this work, such as the presence of different 
characteristics in human versus animal studies, which impeded the immediate comparability of the 
two datasets. One of these constrains was that the dose used to efficiently reduce blood glucose 
and HbA1c levels in animals varied considerably between studies (6-20 mg/kg). Generally speaking, 
higher doses are used in animals than humans. Additionally, in animal studies the impact of 
treatment was detected by a comparison of glucose and HbA1c levels between treatment and 
placebo groups; consequently, single-arm human studies that presented data as compared to 
baseline measurements, i.e. without a placebo control, could not be used in the analysis. Another 
problem was that the age of the study populations differed: the initial ages of human patients 
correspond to late adulthood whereas that of animals represents adolescence and early adulthood. 
Animal models are unique in their predictive value for human drug efficacy. This study aimed to 
present how the predictive validity of animal models can be assessed retrospectively. Our method 
shows that regular reassessment of animal models helps to identify “human relevance of each 
model” and adapt research design for actual research goals. Although our findings are important, 
one should be careful with interpretation of results presented here; extrapolation of our results 
outside the thiazolidinedione class of drugs should be avoided.   
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Supplementary material 
PROTOCOL 
Reviewers 
Primary reviewer: Orsolya E Varga 
Secondary reviewer: Noémi Zsíros 
Involved in the analysis: László Kardos
 
and I Anna S Olsson
1 
Review question/objective 
The main objective of this article is to determine the predictive validity of animal models of 
diabetes, by analyzing which models perform most similarly to humans during rosiglitazone 
treatment in terms of changes in standard diabetes diagnosis parameters (glycosylated hemoglobin 
(HbA1c) and fasting glucose (FG) levels).   
A further objective of this article is to explore the impact of four covariates on the predictive 
capacity of animal models. These covariates are methodological issues which often differ across 
studies, namely i) diabetes induction method, ii) drug administration route, iii) sex of animals, and 
iv) diet during the experiments. 
Background 
We will assess the predictive value – arguably the most important feature of animal models from 
the aspect of human relevance – of several animal models. Predictive validity can be calculated 
retrospectively by obtaining data on treatment efficacy from human and animal trials. In practice, 
the predictive value of different animal models is generally assumed and rarely measured. Using 
rosiglitazone as a case study, a widely used pharmaceutical to treat type 2 diabetes mellitus, we aim 
to provide data on the predictive validity of different animal models of diabetes. Similar analysis has 
not been published in this topic. 
Although this analysis is important from both animal welfare and translational points of view, there 
are limitations. One of the main challenges is the poor quality of published research data from 
human and animal studies. Due to the recent tight regulations on clinical trials, transparency on the 
conduct and results of human clinical trials has been improved. However, there are still problems 
with study design and publication from these trials. Also for animal data, it is increasingly evident 
that shortcomings in research design and publication bias resulting from selective publishing of 
desirable results are the cause of overestimated treatment effects.  
An additional challenge is that of comparing different species.  
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Selection criteria 
Populations 
Humans and animals   
Intervention(s)/Indicator 
Treatment with rosiglitazone (in monotherapy) 
Comparators 
Placebo 
Outcomes 
Glycosylated hemoglobin (HbA1c) and fasting glucose (FG) levels 
Types of studies 
The review will consider original research studies on the treatment effect of rosiglitazone 
Planned search strategy 
The search strategy aims to find both published and unpublished studies.  
Two reviewers perform a first-stage screening of titles and abstracts based on the research question 
and its study design, sample, intervention, and outcome to be studied. Two reviewers will perform 
the second-stage screening of selected full-text articles.  
Inclusion criteria: animal/human research (original studies), treatment effect of rosiglitazone, 
outcome measure is given in not-manipulated data of fasting glucose levels and/or HbA1c.  
Exclusion criteria: no control group, not animal study, no data from outcome measures, 
rosiglitazone was not tested in monotherapy, design problems (eg no variation), not in English. 
Studies published in English will be considered for inclusion in this review. Studies published to 
December 2012 will be considered for inclusion in this review. 
The databases to be searched include: 
MEDLINE, Web of Science. 
The search for unpublished studies will include: 
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GSK company site. Monotherapy studies will be identified and included in the analysis from the 
website of the pharmaceutical company GlaxoSmithKline (GSK) who made all studies on 
rosiglitazone available through the company’s website. 
Animal studies- Initial keywords to be used will be: 
Animal studies will be identified from Pubmed and Web of Science using the following algorithms. 
Pubmed search: ("animal experimentation"[MeSH Terms] OR "models, animal"[MeSH Terms]) AND 
"rosiglitazone"[Supplementary Concept] AND "blood glucose"[MeSH Terms]. Web of Science: 
Topic=(rosiglitazone) AND Topic=(blood glucose) AND Topic=(animal) AND Topic=(search filter 
suggested by Carlijn R Hooijmans: 
Topic=(rosiglitazone) AND Topic=(blood glucose) AND Topic=(animal) AND Topic=(animal OR 
animals OR pisces OR fish OR fishes OR catfish OR catfishes OR sheatfish OR silurus OR arius OR 
heteropneustes OR clarias OR gariepinus OR fathead minnow OR fathead minnows OR pimephales 
OR promelas OR cichlidae OR trout OR trouts OR char OR chars OR salvelinus OR salmo OR 
oncorhynchus OR guppy OR guppies OR millionfish OR poecilia OR goldfish OR goldfishes OR 
carassius OR auratus OR mullet OR mullets OR mugil OR curema OR shark OR sharks OR cod OR 
cods OR gadus OR morhua OR carp OR carps OR cyprinus OR carpio OR killifish OR eel OR eels OR 
anguilla OR zander OR sander OR lucioperca OR stizostedion OR turbot OR turbots OR psetta OR 
flatfish OR flatfishes OR plaice OR pleuronectes OR platessa OR tilapia OR tilapias OR oreochromis 
OR sarotherodon OR common sole OR dover sole OR solea OR zebrafish OR zebrafishes OR danio 
OR rerio OR seabass OR dicentrarchus OR labrax OR morone OR lamprey OR lampreys OR 
petromyzon OR pumpkinseed OR pumpkinseeds OR lepomis OR gibbosus OR herring OR clupea 
OR harengus OR amphibia OR amphibian OR amphibians OR anura OR salientia OR frog OR frogs 
OR rana OR toad OR toads OR bufo OR xenopus OR laevis OR bombina OR epidalea OR calamita 
OR salamander OR salamanders OR newt OR newts OR triturus OR reptilia OR reptile OR reptiles 
OR bearded dragon OR pogona OR vitticeps OR iguana OR iguanas OR lizard OR lizards OR anguis 
fragilis OR turtle OR turtles OR snakes OR snake OR aves OR bird OR birds OR quail OR quails OR 
coturnix OR bobwhite OR colinus OR virginianus OR poultry OR poultries OR fowl OR fowls OR 
chicken OR chickens OR gallus OR zebra finch OR taeniopygia OR guttata OR canary OR canaries 
OR serinus OR canaria OR parakeet OR parakeets OR grasskeet OR parrot OR parrots OR psittacine 
OR psittacines OR shelduck OR tadorna OR goose OR geese OR branta OR leucopsis OR woodlark 
OR lullula OR flycatcher OR ficedula OR hypoleuca OR dove OR doves OR geopelia OR cuneata OR 
duck OR ducks OR greylag OR graylag OR anser OR harrier OR circus pygargus OR red knot OR 
great knot OR calidris OR canutus OR godwit OR limosa OR lapponica OR meleagris OR gallopavo 
OR jackdaw OR corvus OR monedula OR ruff OR philomachus OR pugnax OR lapwing OR peewit 
OR plover OR vanellus OR swan OR cygnus OR columbianus OR bewickii OR gull OR 
chroicocephalus OR ridibundus OR albifrons OR great tit OR parus OR aythya OR fuligula OR 
streptopelia OR risoria OR spoonbill OR platalea OR leucorodia OR blackbird OR turdus OR merula 
OR blue tit OR cyanistes OR pigeon OR pigeons OR columba OR pintail OR anas OR starling OR 
sturnus OR owl OR athene noctua OR pochard OR ferina OR cockatiel OR nymphicus OR 
hollandicus OR skylark OR alauda OR tern OR sterna OR teal OR crecca OR oystercatcher OR 
haematopus OR ostralegus OR shrew OR shrews OR sorex OR araneus OR crocidura OR russula OR 
european mole OR talpa OR chiroptera OR bat OR bats OR eptesicus OR serotinus OR myotis OR 
dasycneme OR daubentonii OR pipistrelle OR pipistrellus OR cat OR cats OR felis OR catus OR 
feline OR dog OR dogs OR canis OR canine OR canines OR otter OR otters OR lutra OR badger OR 
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badgers OR meles OR fitchew OR fitch OR foumart or foulmart OR ferrets OR ferret OR polecat OR 
polecats OR mustela OR putorius OR weasel OR weasels OR fox OR foxes OR vulpes OR common 
seal OR phoca OR vitulina OR grey seal OR halichoerus OR horse OR horses OR equus OR equine 
OR equidae OR donkey OR donkeys OR mule OR mules OR pig OR pigs OR swine OR swines OR 
hog OR hogs OR boar OR boars OR porcine OR piglet OR piglets OR sus OR scrofa OR llama OR 
llamas OR lama OR glama OR deer OR deers OR cervus OR elaphus OR cow OR cows OR bos taurus 
OR bos indicus OR bovine OR bull OR bulls OR cattle OR bison OR bisons OR sheep OR sheeps OR 
ovis aries OR ovine OR lamb OR lambs OR mouflon OR mouflons OR goat OR goats OR capra OR 
caprine OR chamois OR rupicapra OR leporidae OR lagomorpha OR lagomorph OR rabbit OR 
rabbits OR oryctolagus OR cuniculus OR laprine OR hares OR lepus OR rodentia OR rodent OR 
rodents OR murinae OR mouse OR mice OR mus OR musculus OR murine OR woodmouse OR 
apodemus OR rat OR rats OR rattus OR norvegicus OR guinea pig OR guinea pigs OR cavia OR 
porcellus OR hamster OR hamsters OR mesocricetus OR cricetulus OR cricetus OR gerbil OR gerbils 
OR jird OR jirds OR meriones OR unguiculatus OR jerboa OR jerboas OR jaculus OR chinchilla OR 
chinchillas OR beaver OR beavers OR castor fiber OR castor canadensis OR sciuridae OR squirrel OR 
squirrels OR sciurus OR chipmunk OR chipmunks OR marmot OR marmots OR marmota OR suslik 
OR susliks OR spermophilus OR cynomys OR cottonrat OR cottonrats OR sigmodon OR vole OR 
voles OR microtus OR myodes OR glareolus OR primate OR primates OR prosimian OR prosimians 
OR lemur OR lemurs OR lemuridae OR loris OR bush baby OR bush babies OR bushbaby OR 
bushbabies OR galago OR galagos OR anthropoidea OR anthropoids OR simian OR simians OR 
monkey OR monkeys OR marmoset OR marmosets OR callithrix OR cebuella OR tamarin OR 
tamarins OR saguinus OR leontopithecus OR squirrel monkey OR squirrel monkeys OR saimiri OR 
night monkey OR night monkeys OR owl monkey OR owl monkeys OR douroucoulis OR aotus OR 
spider monkey OR spider monkeys OR ateles OR baboon OR baboons OR papio OR rhesus monkey 
OR macaque OR macaca OR mulatta OR cynomolgus OR fascicularis OR green monkey OR green 
monkeys OR chlorocebus OR vervet OR vervets OR pygerythrus OR hominoidea OR ape OR apes 
OR hylobatidae OR gibbon OR gibbons OR siamang OR siamangs OR nomascus OR symphalangus 
OR hominidae OR orangutan OR orangutans OR pongo OR chimpanzee OR chimpanzees OR pan 
troglodytes OR bonobo OR bonobos OR pan paniscus OR gorilla OR gorillas OR troglodytes) 
Human studies-- Initial keywords to be used will be: 
A PubMed search will be used the algorithm: “Blood Glucose”[Mesh] AND “Hemoglobin A, 
Glycosylated”[Mesh] AND “Diabetes Mellitus, Type 2/drug therapy”[Mesh] AND 
“rosiglitazone”[Supplementary Concept] AND “Thiazolidinediones/therapeutic use”[Mesh] AND 
“Randomized Controlled Trial”[ptyp] AND English[lang].  
Planned data extraction 
Two coauthors will download all references into Endnote. Data will be extracted into an excel table 
(Microsoft Office Excel 2007). Data will be extracted on study design elements: the time, route and 
dose of the drug administration, the species and strain of the animal, age and sex/gender of 
subjects, diets, diabetes induction method; and on outcomes, i.e. FG and HbA1c levels (number of 
observations, mean, variability measure) in each study group. 
Where data would be reported graphically, digital online ruler will be used. 
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All data will be manually extracted by two reviewers. 
Quality appraisal 
To reduce bias appropriate research terms will used (eg. Randomized Controlled Trial), research 
papers with no control groups will be excluded and observations will be weighted proportionally to 
their precision (reciprocal of squared standard error of treatment effect) during analysis. 
Data analysis and synthesis 
Quantitative data will be extracted from papers included in further modeling (human-animal 
comparison). The analysis will be stratified according to i) species and strains ii) diabetes induction 
method, iii) drug administration route, iv) sex of animals, and v) diet during the experiments. Data 
will be analyzed with STATA and the significance level will be set at p<0.05. 
 
 
